Transdermal systems having polyisobutylene and methods of making and using them

A transdermal system for delivering a contraceptive to a human patient in need thereof, the transdermal system comprising a backing and a matrix contacting the backing, wherein the matrix comprises ethinyl estradiol and norelgestromin, and the matrix is configured to deliver about 17.5 mcg to about 20 mcg per day of the ethinyl estradiol and about 190 mcg to about 240 mcg per day of the norelgestromin to the human patient during a seven-day wear period.

A transdermal system for delivering a contraceptive to a human patient in need thereof, the transdermal system comprising a backing and a matrix contacting the backing, wherein the matrix comprises ethinyl estradiol and norelgestromin, and the matrix is configured to deliver about 17.5 mcg to about 20 mcg per day of the ethinyl estradiol and about 190 mcg to about 240 mcg per day of the norelgestromin to the human patient during a seven-day wear period, and the matrix further comprises an adhesive comprising a low molecular weight polyisobutylene having an average molecular weight of about 40,000 to about 85,000 and a high molecular weight polyisobutylene having an average molecular weight of about 500,000 to about 1.5 million.

A transdermal system for a human patient, the transdermal system comprising a backing layer, a release liner, and a matrix disposed between the backing layer and the release liner, the matrix comprising norelgestromin, ethinyl estradiol, and an adhesive, the adhesive comprising a first component comprising a medium molecular weight polyisobutylene having an average molecular weight of about 70,000, a first high molecular weight polyisobutylene having an average molecular weight of about 1,050,000 and a second high molecular weight polyisobutylene having an average molecular weight of about 1,550,000;

• and the adhesive also comprising a second component comprising both a medium molecular weight polyisobutylene having an average molecular weight of about 53,000 and a high molecular weight polyisobutylene having an average molecular weight of about 1,550,000, and the first component and the second component having a weight ratio, wherein the weight ratio of the first component to the second component is about 10:90.

A transdermal system for a human patient, the transdermal system comprising a backing layer, a release liner, and a matrix disposed between the backing layer and the release liner, the matrix comprising norelgestromin, ethinyl estradiol, and an adhesive, the matrix being configured to deliver about 17.5 mcg to about 20 mcg per day of the ethinyl estradiol and about 190 mcg to about 240 mcg per day of the norelgestromin to the human patient during a seven-day wear period, the adhesive comprising a polyisobutylene mixture comprising 5.5 wt % of a first medium molecular weight polyisobutylene having an average molecular weight of about 70,000, 75.6 wt % of a second medium molecular weight polyisobutylene having an average molecular weight of about 53,000, 16.65 wt % of a first high molecular weight polyisobutylene having an average molecular weight of about 1,550,000, and 2.25 wt % of a second high molecular weight polyisobutylene having an average molecular weight of about 1,050,000 based on a total weight of the adhesive, wherein the matrix further comprises crospovidone in an amount of 23.19 wt %, dipropylene glycol LO+ in an amount of 0.77 wt %, oleyl alcohol in an amount of 3.64 wt %, and mineral oil in an amount of 12.89 wt % by weight based on a total weight of the matrix.